FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
July 25, 2024 16:30 ET
|
Cellectis Inc.
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies for...
CD19/CD20 Bi-Specific CAR-T Pipeline Research Report 2024: In-depth Analysis of the Pipeline Assets, Therapeutic Assessment and Comparative Analysis
July 18, 2024 07:21 ET
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.CD19/CD20 Bi-Specific CAR-T...
Monthly information on share capital and company voting rights
July 05, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
June 28, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
June 26, 2024 07:00 ET
|
Lyell Immunopharma, Inc
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
Global CAR-T Cell Therapy Market Report 2024: Detailed Coverage of the Approved CAR-T Products, including Regulatory Approvals, Pricing, Reimbursement and Degree of Market Penetration
June 24, 2024 10:00 ET
|
Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. ...
CAR-T Therapy Pipeline Landscape Report, 2024 - Features Insights on Emerging Drugs CT053, Descartes-08, ALLO-501A, CTX110, and IMPT 314
June 14, 2024 06:23 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This report provides in-depth insights into the...
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
June 12, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
CAR T Cell Therapy Market Industry Trends and Global Forecasts to 2035: Rising Leukemia and Lymphoma Cases Boost CAR T Cell Therapy Market, with Positive Phase III Trials Expanding Treatment Potential
June 05, 2024 08:03 ET
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical...
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
June 04, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...